

All cancer sites


Average radiotherapy use



Australia

New South Wales

Victoria



Canada

*Prince Edward Island

Nova Scotia

Newfoundland and Labrador

Manitoba


Alberta

British Columbia

Ontario


New Brunswick

*Saskatchewan



Norway

Norway




UK

Wales

Northern Ireland

Scotland

England



'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk (*).


The use of radiotherapy is low in patients with colon, liver, pancreatic, and ovarian cancers in accordance with clinical practice guidelines.

Oesophageal cancer


Average radiotherapy use vs 1- and 5- year net survival




Australia




Canada



Norway



UK



Average radiotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.
'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.
Jurisdictions with less than 100 patients were excluded.

Colon cancer




Average radiotherapy use vs 1- and 5- year net survival



Australia




Canada



Norway



UK



Average radiotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.
 'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.
 The use of radiotherapy is low in patients with colon cancer in accordance with clinical practice guidelines.


Stomach cancer




Average radiotherapy use vs 1- and 5- year net survival




Australia




Canada



Norway



UK



Average radiotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.
 'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.
 Jurisdictions with less than 100 patients were excluded.

Liver cancer


Average radiotherapy use



Australia




Canada



Norway



UK



'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis. The use of radiotherapy is low in patients with liver cancer in accordance with clinical practice guidelines.

Rectal cancer


Average radiotherapy use vs 1- and 5- year net survival



Australia

New South Wales

Victoria



Canada

Prince Edward Island

Manitoba

New Brunswick

British Columbia


Ontario

Alberta

Nova Scotia


Newfoundland and Labrador

Saskatchewan



Norway

Norway




UK

Northern Ireland

England

Wales

Scotland



Average radiotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.
'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.

Rectal cancer stages II/III


Average radiotherapy use vs 1- and 5- year net survival



Australia

New South Wales

Victoria



Canada

Manitoba

British Columbia

New Brunswick


Ontario

Alberta

Saskatchewan


Nova Scotia

Newfoundland and Labrador



Norway

Norway




UK

Northern Ireland

England

Wales

Scotland



- ◆ Stage II 1-year net survival
- ◆ Stage III 1-year net survival
- Stage II 5-year net survival
- Stage III 5-year net survival

Average radiotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.

'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.

Jurisdictions with less than 100 patients were excluded.


Pancreatic cancer




Average radiotherapy use vs 1- and 5- year net survival




Australia




Canada



Norway



UK



Average radiotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.
 'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.
 The use of radiotherapy is low in patients with pancreatic cancer in accordance with clinical practice guidelines.

Lung cancer


Average radiotherapy use vs 1- and 5- year net survival



Australia

New South Wales

Victoria



Canada

Newfoundland and Labrador

Prince Edward Island

Nova Scotia

Manitoba


Alberta

British Columbia

Ontario


New Brunswick

Saskatchewan



Norway

Norway




UK

Northern Ireland

Wales

Scotland

England



Average radiotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.
'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.

Ovarian cancer


Average radiotherapy use vs 1- and 5- year net survival




Australia




Canada



Norway



UK



Average radiotherapy use data (2012-2017) and survival data (2010-2014) cover different time periods.
 'Overall average use' relates to the average radiotherapy use (%) across all jurisdictions included in the meta-analysis.
 The use of radiotherapy is low in patients with ovarian cancer in accordance with clinical practice guidelines.